ISRCTN30202688已完成不适用
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations
Crucell, Berna Biotech Ltd (Switzerland)0 个研究点目标入组 110 人开始时间: 2009年5月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy female and male volunteers equal to or older than 18 years of age on the day of enrolment
- •2. Written informed consent
排除标准
- •1. Pregnancy and lactation
- •2. Serious adverse reaction to any influenza vaccine
研究者
相似试验
已完成
不适用
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsInfluenzaISRCTN89337058Crucell Switzerland AG (Switzerland)110
已完成
不适用
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in children aged 6 to 35 months in comparison to a commercially available influenza vaccineRespiratoryInfluenza, virus not identifiedInfluenzaISRCTN10483274Berna Biotech Ltd, a Crucell Company (Switzerland)1,239
已完成
不适用
Assessment of the immunogenicity and safety of the Northern Hemisphere 2008/2009-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsInfluenzaISRCTN40098615Crucell, Berna Biotech Ltd (Switzerland)110
已完成
1 期
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
尚未招募
1 期
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana